MENU
LYEL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Lyell Immunopharma (LYEL) Ownership - Who owns Lyell Immunopharma?
Lyell Immunopharma Inc is a clinical-stage cell therapy company... Show more
Profile
Industry
N/A
Address
201 Haskins Way
Phone
+1 650 695-0677
Employees
224
Web
https://www.lyell.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
149.83M
P/E Ratio
N/A
Total Cash
370.53M
Projected Growth
N/A
Total Debt
58.97M
Revenue
61K
Risk (Beta)
-0.56
Dividend Yield
N/A
Total Cash/Share
1.26
Total Debt/Equity
N/A
Revenue/Share
0.00 USD as % of share price
Fundamentals
LYEL
Capitalization
150M
P/E Ratio
N/A
Risk (Beta)
-0.56
Dividend Yield
N/A
Total Cash
371M
Total Cash/Share
1.26
Total Debt
59M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.00%
Revenue
61K
ROE
N/A
Book Value
383M
P/B Ratio
0.39
Cash Flow
N/A
Earnings
-1.31
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
29K
Current Ratio
7.06
Current Revenue Per Employee
36.67
Dividends Per Share - Security
N/A
EBITDA
-200.64M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-55.28
Shares Held By Institutions
131M
Shares Outstanding - Current
295M
Total Liabilities
108M
Total Volume MTD
N/A
Value
-1
Gain YTD
-24.328
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
201 Haskins Way
Phone
+1 650 695-0677
Employees
224
Web
https://www.lyell.com